Cannabis Is Not an Evidence-Based Treatment for Bulimia Nervosa

Bulimia nervosa is a serious eating disorder involving recurrent binge-eating episodes and compensatory behaviors such as self-induced vomiting, fasting, excessive exercise, or misuse of laxatives. Although a person with bulimia may be underweight, at an average weight, or overweight, the disorder can cause potentially life-threatening medical complications, including dehydration, electrolyte abnormalities, gastrointestinal problems, dental erosion, kidney injury, and cardiac arrhythmias.

Because bulimia often occurs alongside depression, anxiety, substance-use disorders, or other psychiatric conditions, treatment usually requires coordinated medical and mental-health care. The National Institute of Mental Health’s overview of eating disorders describes treatment as potentially including psychotherapy, medical monitoring, nutritional counseling, medication, and—in severe cases—hospital or residential care.

What treatment has the strongest evidence?

For adults, eating-disorder-focused cognitive behavioral therapy is a central treatment. Clinical guidance from the American Psychiatric Association also supports using a serotonin reuptake inhibitor, particularly fluoxetine, either alongside therapy or when psychotherapy alone does not produce enough improvement. Treatment may also address nutritional rehabilitation, physical complications, suicidal thoughts, substance use, and other co-occurring conditions.

These treatments are intended to reduce both binge eating and purging while helping patients establish more regular eating patterns and challenge the thoughts and behaviors that maintain the disorder. Family or caregiver involvement can be especially valuable for adolescents and for adults who have appropriate support at home.

What does the research say about cannabis?

There is no good clinical evidence that medical cannabis treats bulimia nervosa. Research on the endocannabinoid system has generated hypotheses about how cannabinoid signaling may be involved in appetite, reward, and eating behavior, but biological plausibility is not the same as proof that cannabis improves bulimia.

For example, a 2011 positron-emission tomography study examined cannabinoid type 1 receptor availability in 16 women with bulimia nervosa, 14 women with anorexia nervosa, and 19 healthy controls. The researchers observed some differences in brain receptor availability, particularly in the insula, but the study did not test cannabis as a treatment and could not show that cannabinoids reduce bingeing or purging. An earlier study measuring blood levels of the endocannabinoid anandamide found no significant increase in women with bulimia nervosa. These studies are useful for understanding possible biology, not for establishing medical cannabis as an effective therapy.

It is also important not to generalize findings from anorexia nervosa, cancer-related appetite loss, or other conditions to bulimia. The treatment goals are different. Increasing appetite or making food more rewarding may be undesirable for someone whose illness includes episodes of loss-of-control eating followed by compensatory behaviors.

Could THC, CBD, or THCV help?

THC can increase appetite and alter mood, perception, memory, and judgment. Those effects could be counterproductive for some people with bulimia, particularly if they intensify binge eating, anxiety, impulsivity, or reliance on a substance to manage distress. CBD and THCV are sometimes promoted as having different effects on appetite or anxiety, but there are no established dosing guidelines or high-quality clinical trials showing that either compound treats bulimia nervosa.

Cannabis can also complicate assessment. Frequent use may contribute to cannabis-use disorder, and prolonged use can cause cannabinoid hyperemesis syndrome—a pattern of recurrent nausea, vomiting, and abdominal pain that may be confused with eating-disorder purging or other gastrointestinal illness. The Centers for Disease Control and Prevention’s cannabis guidance notes that severe nausea or vomiting can occur with cannabis use.

The bottom line

Medical cannabis should not be considered a proven treatment for bulimia nervosa and should not replace evidence-based psychotherapy, medical monitoring, nutritional support, or prescribed medication. If someone with bulimia is using cannabis—or is considering it for anxiety, nausea, appetite, sleep, or mood—they should discuss that use openly with an eating-disorder clinician. A clinician can assess possible benefits, interactions, substance-use risks, and whether vomiting or other symptoms could reflect a medical emergency.

Electrolyte disturbances, fainting, chest palpitations, blood in vomit, severe abdominal pain, confusion, or inability to keep fluids down require urgent medical attention. Early treatment improves the chance of recovery, and help is available even when symptoms have been present for a long time.